Vistagen Therapeutics Inc (VTGN) Stock Price, Quote & News

Company Profile

Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 577 3600

Website: www.vistagen.com

Address:

343 Allerton Avenue, South San Francisco, United States

Merlintrader Apr. 25 at 3:22 PM

$VTGN Vistagen Therapeutics (Nasdaq: $VTGN): Refisolone FDA Green Light, PALISADE-3 Failure and the High-Stakes PALISADE-4 Catalyst https://merlintrader.com/vistagen-therapeutics-april2026-dd/

0 · Reply

skyrockets_Inc Apr. 24 at 4:50 PM

$VTGN I personally believe it will be in the next 2 weeks. In my experience, companies that use the verbiage '1H2026' tend to release their news in that early April-May timeframe, otherwise if they know it's going to be in late May/June they just say 'Q22026' instead. In addition, the PRIMARY COMPLETION DATE for the trial on clinicaltrials.gov website says 4/2026 (see below). Pure speculation but putting all the cookie crumbs together I think data is imminent. If it's delayed into late June it's more likley they are pivoting to a RM or some other strategic play instead imo.

5 · Reply

smooth2222 Apr. 24 at 12:15 PM

$VTGN Expected timeline for P4 to be released?

1 · Reply

MaskMaker Apr. 23 at 11:23 PM

$APCX $IGC $MPU $NXL $VTGN

0 · Reply

ReversedRunners Apr. 23 at 7:45 PM

$VTGN $OCGN **

0 · Reply

ThaDankles Apr. 23 at 7:00 PM

$CHIP.X $VTGN and $AKBA are my current plays. Waiting for $BYND to dump more. I made some good money buying low calls and selling the latest pop. Looking to Do it again. Excited about chip. Excited for the vtgn trial results and AKBA is a slow grinder but should get to 5 at some point if butler gets his head out of his butt!

0 · Reply

Hellodaniel Apr. 23 at 12:30 AM

$VTGN This is a gamble where you can only win if P4 succeeds. Until then, it will likely trade sideways in the $0.6 range. If P4 succeeds, it will lead to a licensing agreement with Fuji Pharmaceutical and result in a huge hit, but if P4 fails, everything will become worthless.

1 · Reply

MakesHerSquirt Apr. 22 at 10:36 PM

$VTGN Sell the news duh ! First time people? Again nothing matters but P4 positive results. 18k + watchers this will explode to $12 if P4 is good, basically $0 if P4 fails.

3 · Reply

Edgebell Apr. 22 at 10:18 PM

$VTGN. Love today!! Solid news. Institutional money in (green) , hammer pattern! This one is ready!!!

0 · Reply

Edgebell Apr. 22 at 9:08 PM

$VTGN folks need to relax. Today gives the setup for partner. They won’t let ride until ready.

0 · Reply

Vistagen Receives FDA “Study May Proceed” Letter Under its Refisolone IND Application, Enabling Further Phase 2 Clinical Development for the Treatment of Vasomotor Symptoms (Hot Flashes) due to Menopause

Mar 17, 2026, 9:00 AM EDT - 5 weeks ago

Vistagen Therapeutics Transcript: Stifel 2026 Virtual CNS Forum

Mar 11, 2026, 4:36 PM EDT - 6 weeks ago

Bragar Eagel & Squire, P.C. Urges Vistagen Therapeutics, Inc. Stockholders to Contact the Firm Regarding the Upcoming March 16th Lead Plaintiff Deadline

Mar 3, 2026, 8:30 AM EST - 7 weeks ago

Vistagen to Participate in Upcoming Investor Conferences

Mar 2, 2026, 3:50 PM EST - 7 weeks ago

Vistagen Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 25, 2026, 8:30 AM EST - 2 months ago

Vistagen to Participate in the 46th Annual TD Cowen Healthcare Conference

Feb 12, 2026, 5:00 PM EST - 2 months ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2026

Feb 12, 2026, 4:30 PM EST - 2 months ago

Vistagen Reports Fiscal Year 2026 Third Quarter Financial Results and Provides Corporate Update

Feb 9, 2026, 5:21 PM EST - 2 months ago

UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Feb 6, 2026, 9:52 AM EST - 2 months ago

VTGN Investors Encouraged to Seek Lead Plaintiff Role in Vistagen Therapeutics Securities Class Actoin Case with Johnson Fistel

Feb 4, 2026, 8:30 AM EST - 2 months ago

Vistagen to Report Fiscal Year 2026 Third Quarter Results and Host Corporate Update Conference Call on February 12, 2026

Jan 29, 2026, 8:24 AM EST - 3 months ago

INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Vistagen Therapeutics

Jan 22, 2026, 10:45 AM EST - 3 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) DEADLINE ALERT – Bernstein Liebhard LLP Reminds Vistagen Therapeutics, Inc. Investors of Upcoming Deadline

Jan 16, 2026, 5:06 PM EST - 3 months ago

VISTAGEN THERAPEUTICS, INC. (NASDAQ: VTGN) INVESTOR ALERT Investors With Large Losses in Vistagen Therapeutics, Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Dec 17, 2025, 12:42 PM EST - 4 months ago

Vistagen's Social Anxiety Disorder Drug Disappoints In Pivotal Late-Stage Study

Dec 17, 2025, 8:30 AM EST - 4 months ago

Vistagen Announces Topline Results from PALISADE-3 Phase 3 Public Speaking Challenge Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder

Dec 1, 2025, 8:30 AM EST - 5 months ago

Vistagen Appoints Nick Tressler as Chief Financial Officer

Nov 26, 2025, 8:30 AM EST - 5 months ago

Vistagen Reports Findings on PH80's Brain and Autonomic Effects in Women with Menopausal Hot Flashes at The Menopause Society 2025 Annual Meeting

Nov 13, 2025, 5:00 PM EST - 5 months ago

Vistagen Therapeutics Earnings Call Transcript: Q2 2026

Nov 13, 2025, 4:30 PM EST - 5 months ago

Vistagen Reports Fiscal Year 2026 Second Quarter Financial Results and Provides Corporate Update

Nov 12, 2025, 3:20 PM EST - 5 months ago

Vistagen Therapeutics Transcript: Stifel 2025 Healthcare Conference

Nov 10, 2025, 8:30 AM EST - 5 months ago

Vistagen to Report Fiscal Year 2026 Second Quarter Results and Host Corporate Update Conference Call on November 13, 2025

Nov 5, 2025, 8:30 AM EST - 6 months ago

Vistagen to Participate in Stifel Healthcare Conference 2025

Nov 3, 2025, 8:30 AM EST - 6 months ago

Vistagen Completes PALISADE-3 Phase 3 Public Speaking Challenge Study for the Acute Treatment of Social Anxiety Disorder

Oct 29, 2025, 8:30 AM EDT - 6 months ago

Vistagen Appoints Paul Edick to its Board of Directors

Oct 16, 2025, 8:30 AM EDT - 6 months ago

Vistagen to Present at The Menopause Society 2025 Annual Meeting

Sep 18, 2025, 2:20 PM EDT - 7 months ago

Vistagen Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Sep 9, 2025, 12:00 PM EDT - 8 months ago

Vistagen Therapeutics Transcript: AGM 2025

Sep 9, 2025, 8:30 AM EDT - 8 months ago

Vistagen to Present at the TD Cowen 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

Aug 7, 2025, 5:00 PM EDT - 9 months ago

Vistagen Therapeutics Earnings Call Transcript: Q1 2026

Aug 7, 2025, 4:30 PM EDT - 9 months ago

Vistagen Reports Fiscal Year 2026 First Quarter Financial Results and Corporate Update

Jul 31, 2025, 8:30 AM EDT - 9 months ago

Vistagen to Report Fiscal Year 2026 First Quarter Results and Host Corporate Update Conference Call on August 7, 2025

Jul 24, 2025, 8:30 AM EDT - 9 months ago

Vistagen to Present at the BTIG Virtual Biotechnology Conference

Jul 15, 2025, 8:30 AM EDT - 10 months ago

Vistagen Honored for Outstanding Workplace Culture and Mental Health Leadership

Jun 25, 2025, 8:30 AM EDT - 10 months ago

Vistagen Appoints Elissa Cote as Chief Corporate Development Officer

Jun 17, 2025, 5:00 PM EDT - 11 months ago

Vistagen Therapeutics Earnings Call Transcript: Q4 2025

Jun 17, 2025, 4:30 PM EDT - 11 months ago

Vistagen Reports Fiscal Year 2025 Financial Results and Provides Corporate Update

Jun 12, 2025, 8:30 AM EDT - 11 months ago

Vistagen to Report Fiscal Year 2025 Financial Results and Host Corporate Update Conference Call on June 17, 2025

Jun 5, 2025, 11:40 AM EDT - 11 months ago

Vistagen Therapeutics Transcript: Jefferies Global Healthcare Conference 2025

Jun 2, 2025, 8:30 AM EDT - 11 months ago

Vistagen on Track to Deliver Topline Data From Fasedienol PALISADE-3 Phase 3 Trial for Acute Treatment of Social Anxiety Disorder in the Fourth Quarter of This Year

May 28, 2025, 8:30 AM EDT - 11 months ago

Vistagen to Present at the Jefferies 2025 Global Life Sciences Conference New York

May 23, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2025 American Society of Clinical Psychopharmacology Conference

Apr 17, 2025, 8:30 AM EDT - 1 year ago

Vistagen Presents New Research on the Impact of Social Anxiety Disorder at The Anxiety and Depression Association 2025 Conference

Mar 19, 2025, 8:30 AM EDT - 1 year ago

Vistagen to Present at the 2025 Anxiety and Depression Association Conference

Mar 18, 2025, 12:00 PM EDT - 1 year ago

Vistagen Therapeutics Transcript: Stifel 2025 Virtual CNS Forum

Mar 4, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in Stifel 2025 Virtual CNS Forum

Mar 3, 2025, 1:30 PM EST - 1 year ago

Vistagen Therapeutics Transcript: TD Cowen 45th Annual Health Care Conference

Feb 20, 2025, 8:30 AM EST - 1 year ago

Vistagen to Participate in the 45th Annual TD Cowen Healthcare Conference

Feb 13, 2025, 5:00 PM EST - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2025

Feb 13, 2025, 4:30 PM EST - 1 year ago

Vistagen Reports Fiscal Year 2025 Third Quarter Financial Results and Corporate Update

Feb 6, 2025, 8:30 AM EST - 1 year ago

Vistagen to Report Fiscal Year 2025 Third Quarter Results and Host Corporate Update Conference Call on February 13, 2025

Feb 5, 2025, 8:30 AM EST - 1 year ago

Vistagen Receives U.S. Patent for AV-101 to Treat Neuropathic Pain

Jan 14, 2025, 8:30 AM EST - 1 year ago

Vistagen Announces Positive Results from Exploratory Phase 2A Study of PH284 in Cancer Cachexia

Jan 10, 2025, 8:30 AM EST - 1 year ago

Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder

Nov 18, 2024, 3:35 PM EST - 1 year ago

Vistagen Therapeutics Transcript: Stifel 2024 Healthcare Conference

Nov 14, 2024, 8:30 AM EST - 1 year ago

Vistagen to Present at the Stifel 2024 Healthcare Conference

Nov 7, 2024, 5:00 PM EST - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q2 2025

Aug 13, 2024, 5:00 PM EDT - 1 year ago

Vistagen Therapeutics Earnings Call Transcript: Q1 2025

Jun 11, 2024, 5:00 PM EDT - 2 years ago

Vistagen Therapeutics Earnings Call Transcript: Q4 2024

Jun 6, 2024, 11:00 AM EDT - 2 years ago

Vistagen Therapeutics Transcript: Jefferies Global Healthcare Conference

May 15, 2024, 4:05 PM EDT - 2 years ago

Vistagen Therapeutics Transcript: RBC Capital Markets 2024 Global Healthcare Conference

Mar 20, 2024, 12:00 PM EDT - 2 years ago

Vistagen Therapeutics Transcript: Stifel Virtual 2024 CNS Day

Mar 6, 2024, 10:30 AM EST - 2 years ago

Vistagen Therapeutics Transcript: TD Cowen 44th Annual Health Care Conference

Feb 13, 2024, 5:00 PM EST - 2 years ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2024

Nov 9, 2023, 5:00 PM EST - 2 years ago

Vistagen Therapeutics Earnings Call Transcript: Q2 2024

Aug 10, 2023, 4:30 PM EDT - 2 years ago

Vistagen Therapeutics Earnings Call Transcript: Q1 2024

Jun 28, 2023, 4:30 PM EDT - 3 years ago

Vistagen Therapeutics Earnings Call Transcript: Q4 2023

Feb 7, 2023, 5:00 PM EST - 3 years ago

Vistagen Therapeutics Earnings Call Transcript: Q3 2023

Nov 10, 2022, 2:00 PM EST - 3 years ago

Vistagen Therapeutics Earnings Call Transcript: Q2 2023

Merlintrader Apr. 25 at 3:22 PM

$VTGN Vistagen Therapeutics (Nasdaq: $VTGN): Refisolone FDA Green Light, PALISADE-3 Failure and the High-Stakes PALISADE-4 Catalyst https://merlintrader.com/vistagen-therapeutics-april2026-dd/

0 · Reply

skyrockets_Inc Apr. 24 at 4:50 PM

5 · Reply

smooth2222 Apr. 24 at 12:15 PM

$VTGN Expected timeline for P4 to be released?

1 · Reply

MaskMaker Apr. 23 at 11:23 PM

$APCX $IGC $MPU $NXL $VTGN

0 · Reply

ReversedRunners Apr. 23 at 7:45 PM

$VTGN $OCGN **

0 · Reply

ThaDankles Apr. 23 at 7:00 PM

0 · Reply

Hellodaniel Apr. 23 at 12:30 AM

1 · Reply

MakesHerSquirt Apr. 22 at 10:36 PM

$VTGN Sell the news duh ! First time people? Again nothing matters but P4 positive results. 18k + watchers this will explode to $12 if P4 is good, basically $0 if P4 fails.

3 · Reply

Edgebell Apr. 22 at 10:18 PM

$VTGN. Love today!! Solid news. Institutional money in (green) , hammer pattern! This one is ready!!!

0 · Reply

Edgebell Apr. 22 at 9:08 PM

$VTGN folks need to relax. Today gives the setup for partner. They won’t let ride until ready.

0 · Reply

marketCaptain Apr. 22 at 8:28 PM

$VTGN Whats up with the pm and ah swings

0 · Reply

marketCaptain Apr. 22 at 8:25 PM

$VTGN Something up?

1 · Reply

Sindi1987 Apr. 22 at 8:09 PM

$VTGN this news are not looking good so far

0 · Reply

To_De_Moon Apr. 22 at 8:02 PM

$VTGN

0 · Reply

Talego77 Apr. 22 at 7:42 PM

$VTGN I have a feeling the evening session might be eventful.

0 · Reply

Sindi1987 Apr. 22 at 7:32 PM

$VTGN this shit should be at 1 by now

0 · Reply

LORAXX Apr. 22 at 7:07 PM

$VTGN It's time. Let's go!

0 · Reply

Dickman777 Apr. 22 at 7:00 PM

$VTGN finally broke .60 lfg!!

0 · Reply

focafoca99 Apr. 22 at 6:41 PM

$VTGN received an FDA study-may-proceed letter under its Refisolone IND, allowing further Phase 2 development for menopausal hot flashes. https://www.rapidticker.com/news/vtgn-vistagen-receives-fda-study-may-d26046

0 · Reply

cashonthebarrelhead Apr. 22 at 5:32 PM

$VTGN Begun trash flipper, you may regret the day you sold them. Better buy them back.

0 · Reply

Goni Apr. 22 at 5:31 PM

$VTGN thanks to whoever bought a ton of my shares this morning for .85 cents :) now do I buy more and put them up for sale at .85 again? or should I take my blessings and leave this accursed stock behind

2 · Reply

cashonthebarrelhead Apr. 22 at 5:21 PM

$VTGN Many misinterpreted the news or got product in clinicals confused....BOTTOM LINE THE NEWS WAS VERY POSITIVE that it got the green light to continue from FDA on their brightest star in their portfolio.

0 · Reply

Market Cap	22.58M
Revenue (ttm)	490,000.00
Net Income (ttm)	-51.42M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-10,493.88%
Debt to Equity Ratio	0.00

Volume	502,000
Avg Vol	805,038
Day's Range	N/A - N/A
Shares Out	39.62M
Stochastic %K	42%
Beta	0.33
Analysts	Hold
Price Target	$0.97